Author(s): Homburg R, Eshel A, Abdalla HI, Jacobs HS
Abstract Share this page
Abstract The addition of biosynthetic human growth hormone (GH) to treatment with human menopausal gonadotrophin (hMG) significantly augmented the ovarian response in four patients treated for in-vivo and three patients treated for in-vitro fertilization who had previously been resistant to hMG. The amount, duration of treatment and daily effective dose of hMG were all reduced by growth hormone. This action of growth hormone offers a new approach to ovulation induction.
This article was published in Clin Endocrinol (Oxf)
and referenced in Reproductive System & Sexual Disorders: Current Research